Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PRE HYPERTENSION AND HEART ATTACK RISKS

Hypertension `just above normal’ too risky

 

BY OUR PHARMA  CORRESPONDENT

10 August, 2005: If prehypertension --blood pressure just above the normal levels-- can be eliminated, we could potentially prevent about 47 per cent of all heart attacks, says a study published in Stroke: Journal of the American Heart Association.

Normal blood pressure is lower than 120/80 millimeters of mercury (mm Hg). Prehypertension is systolic blood pressure between 120 and 139 and/or diastolic pressure between 80 and 89 mm Hg. (Systolic pressure is the force in the arteries when the heart beats and diastolic pressure is the force when the heart is at rest.) Hypertension is blood pressure 140/90 mm Hg or higher. 

Researchers prefer to refer this as a gray zone, where you are not hypertensive but your blood pressure is not normal either. 

More than a year ago, a national committee coined the term "prehypertension" for this gray area. But until this study, physicians and the public knew little about what this term meant. About 59 million people in the United States are prehypertensive. 

Researchers examined existing data from the Framingham Study and found that a prehypertensive person is more than three times more likely to have a heart attack and 1.7 times more likely to have heart disease than a person with normal blood pressure. 

They did not find a significantly increased risk of stroke among those with prehypertension. "This is somewhat surprising, but it may be related to the small number of stroke events in the study," researchers notes, "The differential effect in this gray zone may be mediated through factors other than blood pressure, such as insulin resistance." 

Researchers also investigated the population's attributable risk, which determines how a disease will be impacted if that risk factor were eliminated. 

While classical recommendations of lifestyle modifications such as weight control, regular physical activity and changes in diet for people with prehypertension, these findings raise the question of whether the treatment for prehypertensive patients should be followed more aggressively, they opined.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us